ReviewFrontiers in microbiology2021
Determinants of Unresponsiveness to Treatment in Cutaneous Leishmaniasis: A Focus on Anthroponotic Form Due to
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Mechanistic evaluation of niosomal Rhoifolin in antileishmanial therapy and its additive potential with meglumine antimoniate.Scientific reports · 2026Article
- A 10-year registry-based retrospective study of cutaneous Leishmaniasis in Mashhad, northeastern Iran: Demographic, clinical, and therapeutic profiles of 1537 cases.Parasite epidemiology and control · 2026Article
- Zoonotic leishmaniasis in China: Current status and challenges to elimination.PLoS neglected tropical diseases · 2026Review
- Prevalence, clinical features and determinants of cutaneous leishmaniasis in central Ethiopia.BMC infectious diseases · 2026Article
- Comparison of the efficacy of local thermotherapy versus Glucantime® in the treatment of anthroponotic cutaneous leishmaniasis: a pilot study.Parasitology research · 2025Article
- Identification of CβS and ODC antimony resistance markers in anthroponotic cutaneous leishmaniasis field isolates by gene expression profiling.Parasite epidemiology and control · 2025Article
- An inclusive assessment of apoptosis mechanisms inCurrent research in parasitology & vector-borne diseases · 2025Review
- The Impact of Anthropic and Natural Events on Leishmaniasis Burden, Control Measures, and Public Health Importance.Transboundary and emerging diseases · 2025Review
- Repositioning of moxidectin: a promising approach in cutaneous leishmaniasis therapy.Parasite (Paris, France) · 2025Article
- Unlocking Responsive and Unresponsive Signatures: A Transfer Learning Approach for Automated Classification in Cutaneous Leishmaniasis Lesions.Transboundary and emerging diseases · 2025Article
- Global Dilemma and Needs Assessment Toward Achieving Sustainable Development Goals in Controlling Leishmaniasis.Journal of epidemiology and global health · 2024Review
- Article
- Article
- Micro-costing from healthcare professional's perspective and acceptability of cutaneous leishmaniasis diagnostic tools in Morocco: A mixed-methods study.PLOS global public health · 2024Article
- InhibitingPharmaceuticals (Basel, Switzerland) · 2023Article
- Cutaneous leishmaniasis situation analysis in the Islamic Republic of Iran in preparation for an elimination plan.Frontiers in public health · 2023Review
- Mutual Role of Patients and the Healthcare System in the Control of Cutaneous Leishmaniasis.Transboundary and emerging diseases · 2023Review
- Therapeutic Efficacy ofPharmaceuticals (Basel, Switzerland) · 2022Article
- Therapeutic effects of Lucilia sericata larval excretion/secretion products on Leishmania major under in vitro and in vivo conditions.Parasites & vectors · 2022Article
- Molecular-based detection ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous leishmaniasis (CL) is a curable disease; however, due to various risk factors, unresponsiveness to CL treatments is inevitable. The treatment of CL has been firmly correlated with multiple determinants, such as demographical, clinical, and environmental factors, the host's immune response, poor treatment adherence, the parasite's genetic make-up, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.